English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Growing evidence has demonstrated that aberrant expression of integrin α2β1 might contribute to the invasion, metastasis and drug resistance of non-small cell lung cancer (NSCLC). Thus, the integrin α2β1 targeting 68 Ga-DOTA-A2B1 tracer was validated in NSCLC in contrast to accumulation of the clinically used 18 F-FDG PET tracer to see if 68 Ga-DOTA-A2B1-PET imaging can offer a valuable and critical diagnostic imaging criterion for the identification of phenotypes of aggressive lung cancer.

theranostics

The Use of PET Imaging for Prognostic Integrin α<sub>2</sub>β<sub>1</sub> Phenotyping to Detect Non-Small Cell Lung Cancer and Monitor Drug Resistance Responses

The Use of PET Imaging for Prognostic Integrin α2β1 Phenotyping to Detect Non-Small Cell Lung Cancer and Monitor Drug Resistance Responses

The Use of PET Imaging for Prognostic Integrin α₂β₁ Phenotyping to Detect Non-Small Cell Lung Cancer and Monitor Drug Resistance Responses